Loss of Tissue Immunoreactive Androgen Receptor in Prostate Cancer Presenting Initially as an Intracranial Tumor

Publisher： Karger

E-ISSN： 1423-0399|63|2|130-132

ISSN： 0042-1138

Source： Urologia Internationalis, Vol.63, Iss.2, 1999-12, pp. : 130-132

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Enzalutamide, an androgen receptor signaling inhibitor, induces tumor regression in a mouse model of castration‐resistant prostate cancer

By  

THE PROSTATE, Vol. 73, Iss. 12, 2013-09 ,pp. : 1291-1305

John Wiley & Sons Inc

Access to resources Recommend Favorite

The transcriptional programme of the androgen receptor (AR) in prostate cancer

By  

BJU INTERNATIONAL, Vol. 113, Iss. 3, 2014-03 ,pp. : 358-366

John Wiley & Sons Inc

Access to resources Recommend Favorite

The Role of an Androgen Receptor Polymorphism in the Clinical Outcome of Patients with Metastatic Prostate Cancer

By  

Urologia Internationalis, Vol. 68, Iss. 1, 2002-01 ,pp. : 16-23

Karger

Access to resources Recommend Favorite

Relationship between Glucocorticoid Receptor Signal Pathway and Androgen-Independent Prostate Cancer

By  

Urologia Internationalis, Vol. 81, Iss. 2, 2008-08 ,pp. : 228-233

Karger

Access to resources Recommend Favorite

Relationship between serum response factor and androgen receptor in prostate cancer

By  

THE PROSTATE, Vol. 75, Iss. 15, 2015-11 ,pp. : 1704-1717

John Wiley & Sons Inc

Access to resources Recommend Favorite